ArticleAnnals of surgical oncology2026
Evaluating the Implementation and Maintenance of a Breast Cancer Risk-Assessment and Prevention Program.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundUnderstanding factors associated with successful high-risk breast health programs can aid in the development of similar initiatives. This study evaluated the impact of the Breast Cancer Personalized Risk Assessment, Education, and Prevention (B-PREP) program using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework.
methodsPatients evaluated from January 2017 to September 2024 were retrospectively reviewed from a prospectively maintained database. The number of patients seen over time was used to measure "reach." Chemoprevention uptake was used to measure "effectiveness." We surveyed B-PREP clinicians and staff using the validated Program Sustainability Assessment Tool (PSAT), to assess factors associated with sustainability ("implementation" and "maintenance").
resultThe study identified of 5972 B-PREP patients, 1860 (31.1 %) of whom had a high-risk lesion (HRL). The average time from the first visit to chemoprevention initiation was 57 weeks (median 24 weeks; range, 0-370 weeks). The overall chemoprevention initiation rate was 7.38 %, significantly higher for the patients with HRL (HRL [22.5 %] vs non- HRL [0.5 %]; p < 0.001). Sustained chemoprevention for ≥6 months also was higher with HRL (HRL [15.4 %] vs non-HRL [0.4 %]; p < 0.001). Ten stakeholders evaluated sustainability using the PSAT. The overall average was high (6.13 of 7). Domains on program adaptation (6.69), ongoing program evaluation (6.64), and environmental support (6.55) had the highest average.
conclusionThe comprehensive risk program increased annual chemoprevention use as clinic volume grew. As the program matured, time to chemoprevention initiation decreased. Clinicians noted that a supportive environment, regular program evaluation, and adaptation to changing circumstances were key features contributing to the sustainability of a successful high-risk program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.